Real-world characteristics, testing patterns, and outcomes in patients with tropomyosin receptor kinase fusion cancer from a large pooled clinicogenomic database
Delays between genetic testing and targeted treatment for TRK fusion cancer vary widely—uncovering this gap highlights a concrete opportunity to improve care speed.
Five clinicogenomic databases were pooled to describe care for 451 people with advanced TRK fusion cancer. The analysis found long delays between testing and targeted treatment and substantial variation in survival across tumor types.
What the study was
- Study design
- Pooled international real-world clinicogenomic cohort
- Population
- Patients with advanced or metastatic NTRK fusion cancers
- Sample size
- 451
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- ESMO real world data and digital oncology
Why it surfaced
Large real-world evidence highlights an implementation gap in genomically targeted oncology without qualifying as a novel-treatment trial.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.